Cited by 473Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal β-Catenin Pathway Function in an Alzheimer’s Disease Model

Open access
Kitazawa, Masashi, Cheng, David, Tsukamoto, Michelle R, Koike, Maya A, Wes, Paul D, Vasilevko, Vitaly, Cribbs, David H, LaFerla, Frank M·2011·The Journal of Immunology

Abstract

Inflammation is a key pathological hallmark of Alzheimer’s disease (AD), although its impact on disease progression and neurodegeneration remains an area of active investigation. Among numerous inflammatory cytokines associated with AD, IL-1β in particular has been implicated in playing a pathogenic role. In this study, we sought to investigate whether inhibition of IL-1β signaling provides disease-modifying benefits in an AD mouse model and, if so, by what molecular mechanisms. We report that chronic dosing of 3xTg-AD mice with an IL-1R blocking Ab significantly alters brain inflammatory responses, alleviates cognitive deficits, markedly attenuates tau pathology, and partly reduces certain fibrillar and oligomeric forms of amyloid-β. Alterations in inflammatory responses correspond to reduced NF-κB activity. Furthermore, inhibition of IL-1 signaling reduces the activity of several tau kinases in the brain, including cdk5/p25, GSK-3β, and p38–MAPK, and also reduces phosphorylated tau levels. We also detected a reduction in the astrocyte-derived cytokine, S100B, and in the extent of neuronal Wnt/β-catenin signaling in 3xTg-AD brains, and provided in vitro evidence that these changes may, in part, provide a mechanistic link between IL-1 signaling and GSK-3β activation. Taken together, our results suggest that the IL-1 signaling cascade may be involved in one of the key disease mechanisms for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1100620

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pathological activation of glial cells and release of inflammatory factors involved in neuroinflammation can exacerbate tau pathology via direct or indirect pathways, leading to neuronal damage and cognitive impairment, ultimately aggravating AD pathology.

    “Evidence suggests that the pathological activation of glial cells and the release of inflammatory factors involved in neuroinflammation can exacerbate tau pathology via direct or indirect pathways, leading to neuronal damage and cognitive impairment, ultimately aggravating AD pathology [113, 114].”
  • Proinflammatory cytokines TNFα, IL1β, and IL6 promote tau phosphorylation in neurons.

    “First, the proinflammatory cytokines TNFα, IL1 β, and IL6 have been shown to promote tau phosphorylation in neurons (Bhaskar et al., 2010; Kitazawa et al., 2011; Quintanilla et al., 2004).”
  • IL-1 receptor signalling plays a key role in neuroinflammation-induced tau phosphorylation by enhancing the activity of tau kinases including CDK5/p25, GSK3β, and p38-MAPK.

    “IL-1 receptor signalling is found to play a key role in neuroinflammation-induced tau phosphorylation by enhancing the activity of tau kinases including cyclin-dependent-like kinase 5/p25 (CDK5/p25), glycogen synthase kinase 3β (GSK3β), and p38 mitogen-activated protein kinase (p38-MAPK)60,61.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M.
Affiliations
  • University of California, Irvine (US)
  • Roche Pharmaceuticals , Palo Alto, CA 94304
Corresponding author
  • Kitazawa, Masashi
  • Cheng, David
  • Vasilevko, Vitaly
Venue
The Journal of Immunology
Published
2011-12
Volume
187
Issue
12
Pages
6539-6549
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2129470375
Cited by
473
References
83
Citations by year
2026: 32 · 2025: 42 · 2024: 40 · 2023: 36 · 2022: 43 · 2021: 35 · 2020: 46 · 2019: 31 · 2018: 39 · 2017: 26 · 2016: 30 · 2015: 18 · 2014: 24 · 2013: 17 · 2012: 14
FWCI
11.99
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (4r01ag020241-15)
  • National Institute on Aging (P01AG000538, R01AG020335, P50 AG 16573, R01 AG-020241, AG020241, AG 00538, P50AG016573, RF1AG020241, R01AG20335, R01AG021982)
  • National Institute of Neurological Disorders and Stroke (NS 050895, R01NS050895)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (K99AR054695)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, IL-1β signaling, IL-1 receptor blockade, tau pathology, cognitive impairment, amyloid-beta, NF-κB, tau kinases, GSK3β, CDK5/p25, p38 MAPK, Wnt/β-catenin signaling, S100B, astrocytes, neuroinflammation, 3xTg-AD mice, disease-modifying therapy
MeSH terms
Alzheimer Disease, Animals, Cells, Cultured, Cognition Disorders, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Nerve Growth Factors, S100 Proteins, Neurons, Signal Transduction, NF-kappa B, tau Proteins, Receptors, Interleukin-1, Cell Line, Tumor, beta Catenin, Mice, Interleukin-1beta, S100 Calcium Binding Protein beta Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review